Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.
about
Neurodegeneration in multiple sclerosis: novel treatment strategiesInterferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisOptimizing treatment success in multiple sclerosisThe effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysisClinical correlates of grey matter pathology in multiple sclerosisFingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyFingolimod treatment in multiple sclerosis leads to increased macular volume.Clinical use of brain volumetry.Clinical relevance of brain volume measures in multiple sclerosis.Dehydration affects spinal cord cross-sectional area measurement on MRI in healthy subjects.Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: implications for monitoring atrophy in clinical studies.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review.Use of natalizumab in multiple sclerosis: current perspectives.Brain MRI atrophy quantification in MS: From methods to clinical application.Outcome Measures in Clinical Trials for Multiple Sclerosis.Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study.Neuroimaging in multiple sclerosis: neurotherapeutic implications.Progressive multiple sclerosis and gray matter pathology: an MRI perspective.Advanced MRI in multiple sclerosis: current status and future challengesEnergy failure in multiple sclerosis and its investigation using MR techniques.Drug therapy for multiple sclerosis.Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine.Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques.A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration.Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).MRI correlates of disability progression in patients with CIS over 48 months.Substantial and reversible brain gray matter reduction but no acute brain lesions in ultramarathon runners: experience from the TransEurope-FootRace Project.Retinal nerve fibre layer thinning in patients with clinically isolated optic neuritis and early treatment with interferon-beta.Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis.The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing-remitting multiple sclerosis.Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosisA Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis.
P2860
Q22241472-9A42C2DB-55ED-4E0E-BF95-63FBD77C5281Q24194800-84670D7B-7477-456B-B7AF-F26420E4F69DQ26771968-B1FCC54E-3C99-4526-9BA0-B5A4C5F496CBQ26824991-46CCF53C-C24F-4012-BE94-4906CC9751A7Q26999302-3118E626-C6BD-47A7-8927-6BCC8A7ED7BAQ27011473-BD54F4CE-DEC5-48F2-B810-E2D7F8D92550Q30537200-3B415AB8-9EF1-4FA1-8B03-D2CF63753FEBQ30582479-8D4DBEB8-264F-4492-9525-27173AB65A59Q30738659-A5775663-CAAB-41D3-95F6-DB60DE02D469Q30810873-50F08B0F-E691-497D-A84B-09CA6E67D6BCQ30868361-67CBDCEE-A63D-49EC-B99B-8A335B50CC3FQ30869048-B560F404-468A-4432-927C-ADE3EDE8DBBBQ30965003-8E2F8272-6789-456F-8056-945C05CB6780Q31009149-5A9349DF-A8AD-470F-9900-FDACC03E4595Q31114633-5A0DA436-CFF2-4C87-B092-655A134C254BQ31149648-6E555725-DE78-4975-ABA9-F53970B2ED42Q31160866-56ED8003-726E-4DFB-9D0B-877CA5377AB5Q33658606-354A2328-F70F-4A60-8514-EE237605C87AQ33697898-94296C20-E061-49E7-A5E1-67C8B0C35348Q33806032-FC36993E-BC7F-4058-9B24-783A1ED0F859Q33852170-88A39313-3A0B-4062-BA69-50663E6C0A9EQ33856615-4B3D0AE3-4B07-4B14-8516-2E2540531A63Q33928808-D6EFFBC8-B656-498C-9E20-0CCAB27FBDDAQ33990246-B3F07F25-A257-4FE0-A306-4F8186624805Q34014627-1FFB9D77-69BB-494A-84CC-5F19A4057839Q34136565-C0281CEC-385C-4CD9-840C-24117FB53135Q34171891-FE91CF61-B49C-4702-9CB7-EA55F7B23E30Q34194343-2E1718E0-5DEB-471C-A1FB-373B85D23B05Q34303664-E6E38B94-629E-48CA-8933-321E6B82C0ABQ34409273-8FF229EA-46C3-4070-ADC6-ECC351200531Q34409308-C8A0B269-5894-4344-A720-C05DE97076C7Q34431806-FC749C63-FCA3-48CE-BAC5-6A347CEEA6CBQ34520058-0DC84BD1-63AB-4FA5-82C0-C1E35494FE11Q34525419-F12FE9BA-600D-4328-B262-A9D82993B5BAQ34988315-47BF9394-9D4B-4D38-966B-85066CC08842Q34988393-39E3BB85-7814-49CA-8F49-DB878479669BQ35586845-98EA0D56-EDC5-417C-B75D-60BA56A23DB5Q35747637-AFCF41CD-E653-49DA-86BF-C70B999F3960Q35838665-17C0C91F-316B-440C-BB99-80A60DBECECFQ35938583-15BEBAD6-BA20-4E18-BB69-F8FC4EF876CC
P2860
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of action of diseas ...... changes in multiple sclerosis.
@en
Mechanisms of action of diseas ...... changes in multiple sclerosis.
@nl
type
label
Mechanisms of action of diseas ...... changes in multiple sclerosis.
@en
Mechanisms of action of diseas ...... changes in multiple sclerosis.
@nl
prefLabel
Mechanisms of action of diseas ...... changes in multiple sclerosis.
@en
Mechanisms of action of diseas ...... changes in multiple sclerosis.
@nl
P2093
P1433
P1476
Mechanisms of action of diseas ...... changes in multiple sclerosis.
@en
P2093
E M Frohman
R Zivadinov
P304
P356
10.1212/01.WNL.0000316810.01120.05
P407
P577
2008-07-01T00:00:00Z